Asset Details
Do you wish to reserve the book?
Clinical factors, management, and outcomes of children under 3 years old with central nervous system tumors: single-center experience
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical factors, management, and outcomes of children under 3 years old with central nervous system tumors: single-center experience
Do you wish to request the book?
Clinical factors, management, and outcomes of children under 3 years old with central nervous system tumors: single-center experience
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical factors, management, and outcomes of children under 3 years old with central nervous system tumors: single-center experience
2024
Overview
Purpose
Children under 3 years old represent a notable portion, about 25 to 30%, of all central nervous system tumor (CNS) cases. Their clinical course, prognosis, and treatment significantly differ from older children. This single-center retrospective study aims to comprehensively analyze survival factors in children under three diagnosed with CNS tumors.
Methods
Between April 2012 and December 2023, cases under 3 years of age with CNS tumors diagnosed at our center were retrospectively evaluated.
Results
Among 279 CNS tumor cases, 42 (15%) were evaluated. The 5-year overall and event-free survival rates were 67.4% (95% CI 47.5–81.1) and 39.8% (95% CI 24.2–55.0), respectively. Gender, symptom onset to diagnosis time, pathological neurological findings at diagnosis, and tumor location did not significantly impact survival (
p
> 0.05). However, cases with neurological symptoms showed significantly higher event-free survival rates (
p
< 0.05). Patients with embryonal tumors, metastases, inability for total surgical excision, relapsed/progressive diseases, and who under 1 year old had significantly lower survival rates (
p
< 0.05). Radiotherapy timing did not affect survival (
p
> 0.05). Event-free survival rates remained unchanged after the third year.
Conclusion
The current treatments have been observed to have a positive impact on survival rates. Nonetheless, there is a need for novel treatments for patients with embryonal tumors, metastases, aged under 1 year, and those where total surgical excision is not feasible or in cases with progressive/relapse disease. This study underscores the importance of the first 3 years regarding relapse, progression, or mortality risk.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
